ASBP Stock Soars 80% on Sublingual Patent Filing and Phase 1 Aspirin Trials

Introduction

ASPIRE BIOPHARMA HOLDINGS INC (NASDAQ: ASBP) develops a patent-pending sublingual drug delivery platform designed to enhance absorption and onset of action for various medicines and supplements. Founded in September 2021 and headquartered in Humacao, Puerto Rico, the company’s technology targets pain and inflammation by bypassing the gastrointestinal tract, with applications including analgesics and treatment for other medical conditions.

Corporate Structure and Workforce

With a workforce of 51–200 employees, ASPIRE BIOPHARMA combines expertise in pharmaceutical development, regulatory affairs, and commercial strategy. Key leadership includes interim CEO Kraig Higginson, who oversees regulatory filings and investor communications. The company has filed multiple patent applications, including the most recent omnibus application on October 6, 2025, with the U.S. Patent and Trademark Office to secure intellectual property around its sublingual delivery mechanism and high-dose aspirin formulation.

Sublingual delivery by Jaehyun Kim

Developments and News

• October 6, 2025: Filing of an omnibus patent application (USPTO application pending) to protect the sublingual platform across multiple drug classes.
• May 21, 2025: Presentation at the Sidoti Virtual Investor Conference, outlining clinical trial strategy and commercialization roadmap.
• April 29, 2025: Institutional Review Board (IRB) approval obtained for Phase 1 clinical trial protocols of a fast-acting high-dose aspirin formulation.
• April 11, 2025: Initial production commenced for a single-dose, pre-workout supplement utilizing the company’s powder-form sublingual technology.
• April 9, 2025: Phase 1 single-center clinical study initiated for the lead aspirin candidate, marking the first human trials of Aspire’s proprietary formulation.
• September 3, 2024: Definitive merger agreement signed with PowerUp Acquisition Corp. (Nasdaq: PWUP), facilitating the company’s NASDAQ listing.

Financial and Strategic Analysis

As of market close on November 14, 2025, ASBP shares traded at $0.19, reflecting an 80.61% increase on a volume of 87.5 million shares, following the company’s 8-K filing. This filing disclosed updates on risk management practices, strategic initiatives, and management’s outlook, though it did not include detailed financial results. Earlier 8-K reports on October 17 and November 5 addressed governance changes and other material corporate events. Going forward, securing patent grants and advancing through clinical milestones will influence future funding requirements and investor interest.

Market Position and Industry Context

Aspire operates within the drug delivery market, which is projected to reach substantial global volumes, driven by increasing demand for non-invasive, rapid-onset formulations. Its sublingual platform addresses limitations in bioavailability and gastrointestinal side effects associated with traditional oral dosage forms. By focusing on conditions such as acute pain and inflammation, the company positions itself against established pharmaceutical firms and specialty drug delivery providers. Successful patent issuance and favorable clinical data will be essential for differentiating Aspire’s products and establishing partnerships or licensing agreements.

tl;dr

On November 14, 2025, ASBP stock increased 80.61% to $0.19 on high trading volume after an 8-K revealed updates on strategic initiatives and risk management. The company filed an omnibus patent application on October 6, 2025, for its sublingual delivery technology and has begun Phase 1 clinical trials of a high-dose aspirin formulation. Future drivers include patent approvals and clinical outcome assessments.